340 related articles for article (PubMed ID: 20945403)
1. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
Siejka A; Schally AV; Block NL; Barabutis N
BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
[TBL] [Abstract][Full Text] [Related]
4. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
[TBL] [Abstract][Full Text] [Related]
5. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
[TBL] [Abstract][Full Text] [Related]
7. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
[TBL] [Abstract][Full Text] [Related]
8. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
Horvath JE; Bajo AM; Schally AV; Kovacs M; Herbert F; Groot K
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15048-53. PubMed ID: 12409615
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
11. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
[TBL] [Abstract][Full Text] [Related]
13. The effect of LHRH antagonist cetrorelix in crossover conditioned media from epithelial (BPH-1) and stromal (WPMY-1) prostate cells.
Siejka A; Schally AV; Barabutis N
Horm Metab Res; 2014 Jan; 46(1):21-6. PubMed ID: 23839655
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
Kovacs M; Schally AV
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
[TBL] [Abstract][Full Text] [Related]
15. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.
Yang D; Hou T; Yang X; Ma Y; Wang L; Li B
J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):389-395. PubMed ID: 22684563
[TBL] [Abstract][Full Text] [Related]
17. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
[TBL] [Abstract][Full Text] [Related]
18. Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
Drewa T; Chlosta P
Eur Urol; 2009 Feb; 55(2):e36-7; author reply e38-9. PubMed ID: 18703271
[No Abstract] [Full Text] [Related]
19. Cetrorelix, a gonadotropin-releasing hormone antagonist, induces the expression of melatonin receptor 1a in the gonadotropin-releasing hormone neuronal cell line GT1-7.
Ishii H; Sato S; Yin C; Sakuma Y; Kato M
Neuroendocrinology; 2009; 90(3):251-9. PubMed ID: 19641296
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone receptor gene expression during pubertal development of male rats.
Zapatero-Caballero H; Sanchez-Franco F; Guerra-Perez N; Fernandez-Mendez C; Fernandez-Vazquez G
Biol Reprod; 2003 May; 68(5):1764-70. PubMed ID: 12606421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
